DUBLIN, November 30, 2021--(BUSINESS WIRE)--The "Antibody-Mediated Rejection - Epidemiology Forecast 2030" report has been added to ResearchAndMarkets.com's offering.
This 'Antibody-mediated Rejection (AMR) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the AMR, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The AMR epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The total incident cases of AMR patients are increasing in 7MM during the study period, i.e., 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted AMR symptoms epidemiology segmented as the Transplant incidence of AMR, and Antibody-mediated Rejection cases. The report includes the incident scenario of AMR symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country-wise - AMR Epidemiology
The epidemiology segment also provides the AMR epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total incident cases of AMR associated in 7MM countries were 5,283 in 2020.
As per the estimates, the United States has the largest incident population of AMR.
Among the EU5 countries, France had the highest incident cases of AMR, followed by Spain. On the other hand, Germany had the lowest incident cases, with 260 cases in 2020 in EU5.
Scope of the Report
The AMR report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
The AMR Epidemiology Report and Model provide an overview of the risk factors and global trends of AMR in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report provides insight into the historical and forecasted patient pool of AMR in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of AMR.
The report provides the segmentation of the AMR epidemiology by transplant incidence of AMR in 7MM.
The report provides the segmentation of the AMR epidemiology by antibody-mediated rejection cases in 7MM.
Key Questions Answered
What will be the growth opportunities in the 7MM for the patient population of AMR?
What are the key findings of the AMR epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of AMR across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What are the disease risk, burdens, and unmet needs of the AMR?
What are the currently available treatments of AMR?
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Key Topics Covered:
1 Key Insights
2 Executive summary
4 Epidemiology and Market Methodology
5 Antibody-mediated Rejection (AMR): Market Overview at a Glance
5.1 Total Market Share (%) Distribution of Antibody-mediated Rejection (AMR) in 2017
5.2 Total Market Share (%) Distribution of Antibody-mediated Rejection (AMR) in 2030
6 Antibody-mediated Rejection (AMR): Market Overview at a Glance
6.3 Types of ABR
6.4 Risk Factors
6.5 Clinical features
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Total cases of Antibody-mediated Rejection (AMR) in 7MM
7.4 United States
7.4.1 Transplant Incidence cases in the United States
7.4.2 Antibody-mediated Rejection Cases in the United States
7.5 EU5 Countries
8 KOL Views
For more information about this report visit https://www.researchandmarkets.com/r/dmp4br
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005511/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900